Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Solna – page 6

378 clinical trials in Solna, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Solna at a glance
378
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

378 trials in Solna

Open in trial search

Colitis ulcerative

Recruiting

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Recruiting

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Urinary tract infection

Recruiting

Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Uppsala Universitet

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Neoplasm malignant

Recruiting

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Soft tissue necrosis

Recruiting

Evaluating Hyperbaric Oxygen Treatment in Addition to Standard Care for Patients with Necrotizing Soft-Tissue Infection

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Rigshospitalet

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA

Neoplasm

Recruiting

Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hypochondroplasia

Recruiting

Study on the Effectiveness and Safety of Infigratinib for Children with Hypochondroplasia and Short Stature

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Solna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on advanced cancer treatments, including studies for prostate cancer, melanoma, breast cancer, and lung cancer. Research aims to evaluate new therapeutic approaches and combination treatments.

  • Metastatic Prostate Cancer Therapy
  • Stage III Melanoma Treatment
  • Advanced Breast Cancer Management
  • Early-Stage Lung Cancer Intervention

Studies evaluate innovative therapies and compare their effectiveness to standard treatments.

02 Metabolic and Endocrine Disorders

Research investigating treatments for metabolic conditions and hormonal disorders, including obesity, diabetes, and polycystic ovary syndrome.

  • Obesity Management Studies
  • PCOS Treatment Alternatives
  • Diabetes Response Mechanisms

Trials examine both conventional and alternative therapeutic approaches.

03 Respiratory and Immunological Studies

Investigations into respiratory conditions and immune system responses, focusing on asthma, nasal polyps, and pediatric respiratory disorders.

  • Asthma Treatment Innovation
  • Chronic Rhinosinusitis Management
  • Pediatric Wheezing Prevention

Research aims to develop more effective treatments and preventive strategies.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.